Molecular imaging biomarkers of the tumour microenvironment: Advances in early cancer detection and treatment response monitoring

Molecular imaging of the tumor microenvironment (TME) is an excellent method for identifying cancer at an early stage and monitoring treatment progress. Emerging techniques, such as positron emission tomography (PET), magnetic resonance imaging (MRI), and optical and photoacoustic imaging, allow the examination of large portions of the TME without necessarily incising them. These include low oxygen levels, new blood vessel formation, immunocyte infiltration, alterations in the extracellular matrix, and changes in body energy consumption. The development of new radiotracers, activatable probes, and multimodal nanoparticles has simplified the process of viewing the TME at a higher level and displaying more than one thing at a time. TME imaging aids clinicians in identifying aggressive malignancies at an earlier stage and displays changes in molecules and functions prior to the emergence of structural alterations that are easy to observe. This simplifies the identification and prioritization of risks, thereby accelerating treatment initiation. If doctors can discover TME features without surgery, they can also tailor treatments to each individual, observe the progress of treatments early, and modify treatments based on the behavior of each tumor. In particular, it is difficult to normalize imaging methods, demonstrate that new probes can be used in clinical settings, and relate molecular imaging data to data from other omics platforms. Therefore, the design of finer and more valid probes is required. Multicentre clinical trials are needed to determine the ability of TME imaging biomarkers to predict outcomes. Finally, we would like AI to create models that will assist us in examining photographs and making better conjectures. There is a continual improvement in molecular imaging tools. They would be able to change the way cancer is managed by simplifying the process of early stage detection, tailoring treatment to an individual, and improving their lives. • Molecular imaging enables noninvasive characterization of key tumor microenvironment components, such as hypoxia, angiogenesis, and immune infiltration. • Novel radiotracers, molecular probes, and nanoparticle-based imaging agents target the tumor microenvironment for early cancer detection and treatment monitoring. • Emerging molecular imaging modalities include positron emission tomography, magnetic resonance imaging, optical imaging, and photoacoustic imaging. • Recent advances in molecular probes have improved the accuracy, sensitivity, and versatility of tumor microenvironment imaging. • Tumor microenvironment-targeted molecular imaging enables early cancer detection by visualizing functional changes before structural alterations appear. • Real-time monitoring of the tumor microenvironment during treatment allows for personalized therapy adaptation and early detection of resistance or recurrence. • Imaging baseline tumor microenvironment characteristics serves as a powerful prognostic tool for predicting disease aggressiveness, treatment response, and patient survival.